Detalhe da pesquisa
1.
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
Clin Infect Dis
; 78(1): 144-148, 2024 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37606512
2.
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Clin Infect Dis
; 75(6): 1006-1013, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35028659
3.
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Clin Infect Dis
; 75(8): 1307-1314, 2022 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243494
4.
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Am J Respir Crit Care Med
; 198(5): 657-666, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954183
5.
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
BMC Infect Dis
; 16(1): 453, 2016 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27567500
6.
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Am J Respir Crit Care Med
; 199(9): 1167-1168, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30645140